Dupilumab: Phase III data

The double-blind, international Phase III LIBERTY AD CHRONOS trial in 740 patients with inadequately controlled moderate to severe atopic dermatitis showed that 300 mg subcutaneous dupilumab once

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE